In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nucletron separates from Delft; looks towards half-billion-dollar mark

This article was originally published in Clinica

Executive Summary

Radiation oncology specialist Nucletron has targeted a three-fold increase in revenue within the next five years, following its recent successful spin-off from parent company Delft Instruments. Over the last few years, Delft has been selling many of its non-core subsidiaries in an attempt to focus on the oil and gas industry. This led to Nucletron proposing a management buy-out. The separation, which took effect from July 1, provides Nucletron with its own share capital and allows the company to progress towards a proposed employee-wide shareholding. Nucletron recorded sales of E120m ($165m) in 2006, but since becoming an independent player situated in the top four radiotherapy companies worldwide, the Dutch firm believes it can close the gap on the top three radiotherapy oncology giants Siemens, Elekta and Varian Medical Systems.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts